RankingsPricing
  1. US-listed companies
  2. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.RGLS

Market cap
$34.58M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Cash and cash equivalents4118371615141434316024
Short-term investments5896122986147----15
Restricted cash---------00
Prepaid materials, net----6544333
Prepaid expenses and other current assets13584211222
Total current assets9911716513487671940376544
Property and equipment, net--------001
Intangibles, net11111110000
Right of use asset---------32
Other assets0120010000-
Total assets104123171141101782842386847
Accounts payable01236621100
Accrued liabilities13466541111
Accrued research and development expenses--------111
Accrued compensation11222222222
Debt, Current-----2017155-5
Other current liabilities-------3313
Total current liabilities131035131433272212512
Operating lease liability, less current portion---------22
Long-Term Debt, Excluding Current Maturities----20----5-
Other long-term liabilities11120-00-1-
Total liabilities4130391745433422121313
Class A-2 Convertible Preferred Stock---------00
Class A-4 Convertible Preferred Stock---------00
Common Stock, Value, Issued00000000000
Additional paid-in capital---316329381387431453510516
Accumulated other comprehensive loss-0-0-0-0-0-0-----0
Accumulated deficit-60-79-136-192-273-346-393-411-427-455-483
Total stockholders’ equity62931321245635-620265533
Total liabilities and stockholders’ equity104123171141101782842386847